Bone Health and GLP-1s: New Data Clears Up 2026 Confusion
Early 2026 warnings about GLP-1 induced osteoporosis clash with new August 2026 research showing a 21% drop in fracture risk for Type 2 diabetics.
Aug 29, 2026
0 10
Science. Treatment. Real-world outcomes.
Stay Ahead of the GLP-1 Revolution
GLP-1 & Metabolic Health News delivers timely, evidence-based reporting on GLP-1 agonists, diabetes care, weight-management therapies, and metabolic research — clear, practical, and sourced from clinical experts.
Weekly briefings
Independently funded
Expert-vetted content
Latest Articles
New research, clinical updates, and patient stories
BMJ Study Links GLP-1 Drugs to Higher Hair Loss Risk
Major new study links popular weight loss drugs to increased alopecia risk. Analysis of 550,000 patients shows higher rates of hair loss compared to other diabetes meds.
Aug 18, 2026
0 16
Shifting GLP-1 Delivery: Oral Approvals and Monthly Dosing in 2026
Explore how 2026 marks a pivotal shift in GLP-1 administration, featuring the first FDA-approved oral non-peptide option, monthly injectable pipelines, and new clinical perspectives on metabolic health.
Aug 8, 2026
0 21
Most Read
Popular guides and in-depth analyses
Untitled
Jun 4, 2026
0 44
REDEFINE-4: CagriSema Misses Non-Inferiority Against Tirzepatide
Novo Nordisk's Combination Therapy Delivers Strong Weight Loss, Yet Fails Head-to-Head Benchmark In a definitive test of mechanism-driven synergy, Novo Nordisk'...
May 25, 2026
0 49
Oral Wegovy, higher‑dose semaglutide, and compounding limits reshape GLP‑1 market
Lede Two regulatory actions this winter — the FDA's approval of an oral Wegovy pill and a new higher‑dose semaglutide injection — plus a proposed FDA curtailing...
May 10, 2026
0 35
Explore Topics
Navigate by condition, treatment, or research area
Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps
Fda Flags Novo Nordisk Over Glp-1 Safety Reporting Gaps On March 5, 2026, the U.S. Food and Drug Administration issued a formal warning letter to Novo Nordisk I...
May 29, 2026
0 51
REDEFINE-4: CagriSema Misses Non-Inferiority Against Tirzepatide
Novo Nordisk's Combination Therapy Delivers Strong Weight Loss, Yet Fails Head-to-Head Benchmark In a definitive test of mechanism-driven synergy, Novo Nordisk'...
May 25, 2026
0 49
Beyond Efficacy: The Real-World Challenges of GLP-1 Adherence
In the rapidly evolving landscape of metabolic health, the arrival of dual GIP/GLP-1 receptor agonists and potent GLP-1 analogues has marked a therapeutic water...
Jun 1, 2026
0 44
Why GLP-1 & Metabolic Health News
Trusted, timely reporting on therapies and metabolism for clinicians, patients, and researchers — focused on evidence, context, and practical relevance.
Evidence-Based Reporting
Summaries and analyses grounded in peer-reviewed studies, clinical trials, and official guidelines.
Clinical Context
Actionable insights for clinicians on dosing, monitoring, side-effect management, and patient counseling.
Patient-Focused
Clear explanations, lived-experience perspectives, and resources to help patients navigate treatment choices.
Expert Contributors
Content informed by endocrinologists, researchers, pharmacists, and other specialists to ensure accuracy.
Policy & Access
Coverage of regulatory approvals, reimbursement developments, and market access that affect care delivery.
Newsroom Speed
Fast, careful coverage of breaking studies and guideline changes with follow-up analysis.
Free Access
Get our free newsletter
Weekly summaries, top stories, and practical tips delivered to your inbox at no cost.
Weekly research roundup
Treatment and safety highlights
Subscriber-only briefings
Stay Informed
Join clinicians, patients, and researchers who rely on concise, accurate coverage of GLP-1 therapies and metabolic health.
Subscribe FreeJoin the mailing list
Get new posts from GLP-1 & Metabolic Health News
Be the first to know when fresh articles are published.